Sale!

Neuronal Paraneoplastic Autoantibodies Profile Ultra Test Cost

Original price was: 3,380 د.إ.Current price is: 3,040 د.إ.

-10%

The “Neuronal Paraneoplastic Autoantibodies Profile Ultra Test” is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect the presence of specific autoantibodies associated with paraneoplastic neurological syndromes (PNS). These syndromes are rare disorders triggered by an immune response to certain cancers, where the immune system mistakenly attacks parts of the nervous system, leading to neurological symptoms. The test aims to identify a range of autoantibodies that target neuronal tissues, providing crucial information for the diagnosis and management of PNS. This can be particularly important for identifying underlying malignancies at an early stage, allowing for timely treatment interventions. The cost of the test is 3040 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology used to achieve accurate results. Conducted at DNA Labs UAE, a facility known for its advanced diagnostic capabilities, this test represents a critical tool in the early detection and management of paraneoplastic neurological syndromes, offering hope for affected patients through targeted therapy and interventions.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

NEURONAL PARANEOPLASTIC AUTOANTIBODIES PROFILE ULTRA Test

At DNA Labs UAE, we offer the NEURONAL PARANEOPLASTIC AUTOANTIBODIES PROFILE ULTRA Test. This diagnostic test is designed to detect autoantibodies associated with paraneoplastic neurological disorders. These rare conditions occur when the immune system mistakenly attacks the nervous system in response to an underlying cancer.

Test Components

  • Amphiphysin
  • CV2
  • PNMA2 (Ma2/Ta)
  • ANNA-1/Hu
  • ANNA-2/Ri
  • PCA-1/Yo
  • SOX1
  • Titin
  • Recoverin
  • Zic4
  • GAD-65
  • Tr (DNER)

Test Price

The cost of the NEURONAL PARANEOPLASTIC AUTOANTIBODIES PROFILE ULTRA Test is AED 3040.0.

Sample Condition

A minimum of 2 mL (1 mL minimum) serum from 1 SST is required for the test. The sample should be shipped refrigerated or frozen.

Report Delivery

Sample collection is available from Monday to Saturday by 9 am, and the report will be delivered on the same day.

Method

The NEURONAL PARANEOPLASTIC AUTOANTIBODIES PROFILE ULTRA Test is conducted using the immunoblot method.

Test Type

This test is specifically designed for the diagnosis of Paraneoplastic Syndromes.

Referring Doctor

The NEURONAL PARANEOPLASTIC AUTOANTIBODIES PROFILE ULTRA Test is typically referred by an Oncologist.

Test Department

This test is conducted in the IMMUNOPATHOLOGY department.

Pre Test Information

No special preparation is required before taking the test.

Test Details

The NEURONAL (PARANEOPLASTIC) AUTOANTIBODIES PROFILE ULTRA Test is a diagnostic test used to detect autoantibodies associated with paraneoplastic neurological disorders. These disorders occur when the immune system mistakenly attacks the nervous system in response to an underlying cancer.

The test involves analyzing a blood sample for the presence of specific autoantibodies that are known to be associated with paraneoplastic neurological disorders. These autoantibodies target proteins found in the nervous system, and their presence can help in the diagnosis and management of these disorders.

The NEURONAL (PARANEOPLASTIC) AUTOANTIBODIES PROFILE ULTRA Test is usually ordered when a patient presents with neurological symptoms suggestive of a paraneoplastic disorder. These symptoms may include muscle weakness, difficulty walking, loss of coordination, sensory abnormalities, and cognitive changes.

The test results provide valuable information to healthcare professionals, helping them identify the specific autoantibodies present and potentially determine the type of cancer associated with the paraneoplastic disorder. This information guides further diagnostic testing and treatment decisions.

It is important to note that the test results should be interpreted in conjunction with the patient’s clinical presentation and other diagnostic findings. A positive test result does not confirm the presence of a paraneoplastic disorder as these autoantibodies can also be found in other conditions or even in healthy individuals. Therefore, further evaluation and consultation with a specialist are usually required for a definitive diagnosis.

Test Name NEURONAL PARANEOPLASTIC AUTOANTIBODIES PROFILE ULTRA Test
Components *Amphiphysin*CV2*PNMA2(Ma2/Ta) *ANNA-1/Hu*ANNA-2/Ri*PCA-1/Yo *SOX1 *Titin*Recoverin*Zic4*GAD-65*Tr (DNER)
Price 3040.0 AED
Sample Condition 2 mL (1 mL min.) serum from 1 SST. Shiprefrigeratedorfrozen..
Report Delivery Sample Mon through Satby 9 am;ReportSameday
Method Immunoblot
Test type Paraneoplastic Syndromes
Doctor Oncologist
Test Department: IMMUNOPATHOLOGY
Pre Test Information No special preparation required
Test Details

The NEURONAL (PARANEOPLASTIC) AUTOANTIBODIES PROFILE ULTRA Test is a diagnostic test used to detect autoantibodies that are associated with paraneoplastic neurological disorders. These disorders are a group of rare conditions that occur when the immune system mistakenly attacks the nervous system in response to an underlying cancer.

The test involves analyzing a blood sample for the presence of specific autoantibodies that are known to be associated with paraneoplastic neurological disorders. These autoantibodies target proteins found in the nervous system, and their presence can help in the diagnosis and management of these disorders.

The NEURONAL (PARANEOPLASTIC) AUTOANTIBODIES PROFILE ULTRA Test is typically ordered when a patient presents with neurological symptoms that are suggestive of a paraneoplastic disorder. These symptoms may include muscle weakness, difficulty walking, loss of coordination, sensory abnormalities, and cognitive changes.

The test results can provide valuable information to healthcare professionals, helping them to identify the specific autoantibodies present and potentially determine the type of cancer that may be associated with the paraneoplastic disorder. This information can guide further diagnostic testing and treatment decisions.

It is important to note that the test results should be interpreted in conjunction with the patient’s clinical presentation and other diagnostic findings. A positive test result does not necessarily confirm the presence of a paraneoplastic disorder, as these autoantibodies can also be found in other conditions or even in healthy individuals. Therefore, further evaluation and consultation with a specialist are usually required for a definitive diagnosis.